4 transcripts
RVMD
Earnings call transcript
NASDAQ
2024 Q2
7 Aug 24
-6236 monotherapy. These data have increased our confidence in the promise of this program and reinforce our commitment to initiate our first
RVMD
Earnings call transcript
NASDAQ
2024 Q1
8 May 24
communicate that and the reasons for doing so. But right now, we are committed to a second-line single-agent non-small cell lung cancer study for RMC-6236
RVMD
Earnings call transcript
NASDAQ
2023 Q4
26 Feb 24
and a highly talented and motivated team. We remain committed to discovering, developing and delivering innovative targeted therapies for patients
RVMD
Earnings call transcript
NASDAQ
2023 Q2
8 Aug 23
down the road? Then I've got a follow-up.
Yes. I think there are 2 parts to the answer. The first part, Alec, is very much we're committed to as much
- Prev
- 1
- Next